Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide)

The buccal mucosa providing direct entry into the systemic circulation appears to be a potential site for the delivery of PACAP (pituitary adenylate cyclase-activating polypeptide), a new therapeutic agent in the treatment of type 2 diabetes. In order to reach a sufficient buccal bioavailability a drug delivery system with strong permeation enhancing and mucoadhesive properties is needed. In this study the enhancing effect of a strongly mucoadhesive chitosan-thioglycolic acid (TGA) conjugate in combination with reduced glutathione (GSH) on the permeation of PACAP across the buccal mucosa was investigated. The apparent permeability coefficient (Papp) of PACAP in buffer only was (5.7 ± 3.1) × 10−8, while in the presence of chitosan-TGA conjugate (1%) a Papp of (20.0 ± 3.4) × 10−8 was achieved. The combination of chitosan-TGA (1%) with GSH (2%) led to an improvement of the Papp up to (57.3 ± 31.7) × 10−8. Release studies of PACAP demonstrated that a controlled release can be provided from tablets consisting of chitosan-TGA at a pH of 5, whereas more than twice as much was released from chitosan-TGA tablets pH 4. According to the combination of permeation enhancing properties, controlled drug release and the mucoadhesive character, chitosan-TGA conjugates represent a promising tool for the buccal administration of PACAP.